Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calabresi, P. A.
Right arrow Articles by Whartenby, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calabresi, P. A.
Right arrow Articles by Whartenby, K. A.
Related Collections
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow Multiple sclerosis
Neurology 2002;58:314-317
© 2002 American Academy of Neurology
Brief Communications

An open-label trial of combination therapy with interferon ß-1a and oral methotrexate in MS

P. A. Calabresi, MD, J. L. Wilterdink, MD, J. M. Rogg, MD, P. Mills, RN, A. Webb and K. A. Whartenby, PhD

From the Department of Neurology (Dr. Calabresi), University of Maryland School of Medicine, Baltimore; and Departments of Clinical Neurosciences (Drs. Calabresi, Wilterdink, and Whartenby, and P. Mills and A. Webb) and Radiology (Dr. Rogg), Brown University School of Medicine, Providence, RI.

Address correspondence and reprint requests to Dr. P.A. Calabresi, Department of Neurology, University of Maryland School of Medicine, 655 W. Baltimore Street, Room 12-027, Baltimore, MD 21201; e-mail: pcala001{at}umaryland.edu

An open-label study was performed to evaluate the safety and efficacy of combination therapy with weekly oral methotrexate (20 mg) and interferon ß-1a (IFNß-1a) in 15 patients with MS who had experienced exacerbations while receiving IFNß monotherapy. Nausea was the only major side effect. A 44% reduction in the number of gadolinium-enhanced lesions seen on MRI scan was observed during combination therapy (p = 0.02). There was a trend toward fewer exacerbations. This combination therapy appears to be safe and well tolerated, and should be studied in a controlled trial.




This article has been cited by other articles:


Home page
 Mult SclerHome page
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al.
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
A. Minagar, J. S. Alexander, R. N. Schwendimann, R. E. Kelley, E. Gonzalez-Toledo, J. J. Jimenez, L. Mauro, W. Jy, and S. J. Smith
Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial
Arch Neurol, February 1, 2008; 65(2): 199 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
F. Mastronardi, H. Tsui, S. Winer, D. Wood, T. Selvanantham, C. Galligan, E. Fish, H-M. Dosch, and M. Moscarello
Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinating diseases
Multiple Sclerosis, June 1, 2007; 13(5): 596 - 609.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. A Farrell and G. Giovannoni
Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis
Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
A. S. Paintlia, M. K. Paintlia, I. Singh, and A. K. Singh
Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis
Am. J. Pathol., September 1, 2006; 169(3): 1012 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. Gonzalez-Rey, A. Fernandez-Martin, A. Chorny, J. Martin, D. Pozo, D. Ganea, and M. Delgado
Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Autoimmune Encephalomyelitis: Down-Regulation of Inflammatory and Autoimmune Responses
Am. J. Pathol., April 1, 2006; 168(4): 1179 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M Pulicken, C N Bash, K Costello, A Said, C Cuffari, J L Wilterdink, J M Rogg, P Mills, and P A Calabresi
Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis
Multiple Sclerosis, April 1, 2005; 11(2): 169 - 174.
[Abstract] [PDF]

Home page
 NeurologyHome page
D. R. Jeffery
Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis
Neurology, December 28, 2004; 63(12_suppl_6): S41 - S46.
[Abstract] [Full Text]

Home page
 NeurologyHome page
S. A. Rizvi and K. Bashir
Other therapy options and future strategies for treating patients with multiple sclerosis
Neurology, December 28, 2004; 63(12_suppl_6): S47 - S54.
[Abstract] [Full Text]

Home page
 NeurologyHome page
W. H. Stuart and P. Vermersch
Concomitant therapy for multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S28 - S34.
[Abstract] [Full Text]

Home page
 NeurologyHome page
P. A. Calabresi
Considerations in the treatment of relapsing-remitting multiple sclerosis
Neurology, April 23, 2002; 58(90084): S10 - 22.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.